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Multiple-dose activated charcoal in acute self-poisoning: 
a randomised controlled trial
Michael Eddleston, Edmund Juszczak, Nick A Buckley, Lalith Senarathna, Fahim Mohamed, Wasantha Dissanayake, Ariyasena Hittarage, 
Shifa Azher, K Jeganathan, Shaluka Jayamanne, M H Rezvi Sheriﬀ , David A Warrell for the Ox-Col Poisoning Study collaborators 
Summary
Background The case-fatality for intentional self-poisoning in the rural developing world is 10–50-fold higher than 
that in industrialised countries, mostly because of the use of highly toxic pesticides and plants. We therefore aimed to 
assess whether routine treatment with multiple-dose activated charcoal, to interrupt enterovascular or enterohepatic 
circulations, oﬀ ers beneﬁ t compared with no charcoal in such an environment.
Methods We did an open-label, parallel group, randomised, controlled trial of six 50 g doses of activated charcoal at 
4-h intervals versus no charcoal versus one 50 g dose of activated charcoal in three Sri Lankan hospitals. 4632 patients 
were randomised to receive no charcoal (n=1554), one dose of charcoal (n=1545), or six doses of charcoal (n=1533); 
outcomes were available for 4629 patients. 2338 (51%) individuals had ingested pesticides, whereas 1647 (36%) had 
ingested yellow oleander (Thevetia peruviana) seeds. Mortality was the primary outcome measure. Analysis was by 
intention to treat. The trial is registered with controlled-trials.com as ISRCTN02920054.
Findings Mortality did not diﬀ er between the groups. 97 (6·3%) of 1531 participants in the multiple-dose group died, 
compared with 105 (6·8%) of 1554 in the no charcoal group (adjusted odds ratio 0·96, 95% CI 0·70–1·33). No 
diﬀ erences were noted for patients who took particular poisons, were severely ill on admission, or who presented 
early.
Interpretation We cannot recommend the routine use of multiple-dose activated charcoal in rural Asia Paciﬁ c; 
although further studies of early charcoal administration might be useful, eﬀ ective aﬀ ordable treatments are urgently 
needed.
Introduction
Treatment of self-poisoning involves resuscitation, 
antidotes, gastric decontamination, and supportive care.1,2 
However, no evidence of beneﬁ t from gastric decontam-
ina tion exists, resulting in widespread debate about the 
role of forced emesis, gastric lavage, and activated 
charcoal in the management of poisoned patients.3–6 
Since few self-poisoning patients die in hospital in 
developed countries,7 decontamination seems unlikely to 
oﬀ er much beneﬁ t and its routine use is no longer 
recommended in these regions.8,9
Self-poisoning in the rural developing world, however, 
is quite diﬀ erent. Highly toxic pesticides and plants are 
ingested rather than pharmaceuticals and the resulting 
 case-fatality is 10–50-fold higher than in developed 
countries.10 Self-poisoning causes more than 
300 000 deaths each year in the Asia Paciﬁ c region 
alone.11,12 Eﬀ ective therapies to improve treatment 
outcomes are urgently needed.
Activated charcoal is the only form of gastrointestinal 
decontamination that is still widely used.13 It is regarded 
as safe and volunteer studies show that early 
administration of one dose of activated charcoal can 
adsorb poison in the stomach and reduce absorption.14 
Charcoal might also work long after ingestion, by 
interruption of enterohepatic and enterovascular cycling 
of poison.15 Multiple doses of activated charcoal are 
therefore given to some patients, irrespective of delay in 
presentation, to increase poison elimination.16 No 
evidence for clinical beneﬁ t from single-dose or 
multiple-dose activated charcoal regimens exists.14,17
Few patients present to hospital within 1–2 h in rural 
Asia; therefore, only one dose of activated charcoal is 
unlikely to oﬀ er beneﬁ t. By contrast, since charcoal 
might increase poison elimination several hours after 
its ingestion, several doses of activated charcoal might 
prove beneﬁ cial in such regions. Most Sri Lankan 
patients ingest either organo phosphorus pesticides or 
yellow oleander (Thevetia peruviana) seeds, both of 
which are known to bind to activated charcoal.18,19 We 
therefore set up a trial to assess whether multiple doses 
of activated charcoal, compared with no charcoal, 
would reduce the rate of death and complications in 
self-poisoned patients in rural Sri Lanka. To distinguish 
whether any eﬀ ect seen with multiple doses was a 
result of the ﬁ rst dose or all six doses, a third group of 
single-dose activated charcoal was added to the study.
Methods
Participants and procedures
The protocol for this randomised, controlled trial has 
been published.20 The trial was done in secondary referral 
hospitals in Anuradhapura, Polonnaruwa, and 
Kurunegala, Sri Lanka. We approached all patients with 
poison ingestion admitted to adult wards. The exclusion 
criteria were: age less than 14 years; treatment with 
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charcoal during this episode; known pregnancy; ingestion 
of a corrosive or a hydrocarbon alone; need for medicine 
given orally; inability of medical staﬀ  to intubate the 
patient with a Glasgow coma score (GCS) less than 13; 
presentation more than 72 h after ingestion; and previous 
recruitment. All patients with poisoning presenting to 
hospital were admitted to the wards. The poison was 
identiﬁ ed from the patient, relatives, or referring doctor’s 
letter, or by the clinical syndrome expressed by the 
patient. We have noted that such historical reporting of 
poison ingested is highly accurate in this cohort.19,21,22
The primary aim was to determine whether routine 
treatment with multiple-dose activated charcoal reduced 
death and complications after acute self-poisoning 
compared with no charcoal. We also wanted to assess 
whether any eﬀ ect noted with multiple-dose activated 
charcoal was a result of the ﬁ rst or subsequent doses of 
charcoal, therefore a single-dose activated charcoal 
treatment was added to the trial. We examined whether 
any beneﬁ t was consistent across the prespeciﬁ ed 
subgroups—organophosphorus or carbamate pesticides, 
yellow oleander,23 and pharmaceutical drugs—and whether 
any eﬀ ect was dependent on time from ingestion to 
treatment or severity on admission (asymptomatic, 
symptomatic with GCS 14 or 15, or symptomatic with a 
GCS <14).
Patients were randomised (with equal probability) to 
receive no charcoal, one 50 g dose of activated charcoal 
(Carbomix, Norit, Amersfoort, Netherlands; 2000 m2/g) 
dissolved in 300 mL of water, or 50 g every 4 h for six doses. 
Stratiﬁ ed block randomisation was done with the following 
strata: (1) substance ingested; (2) time between poisoning 
and recruitment (<1 h; 1–4 h; >4 h; unknown); (3) status on 
admission (asymptomatic, symptomatic [GCS 14 or 15], 
symptomatic [GCS <14]); and (4) hospital  site. For each 
stratum, computer generated random allocation sequences 
with variable block sizes (3, 6, 9) were concealed within a 
Microsoft Access programme written for patient 
recruitment, randomisation, and event recording. The 
allocation sequence was generated independently by the 
study statistician and programmer. Randomisation 
occurred after patients’ details had been entered and 
receipt of consent noted, and could not be manipulated by 
recruiting doctors. Study doctors administered the 
charcoal; conscious patients drank the charcoal, and 
unconscious patients with protected airways received it by 
nasogastric tube. The study was not masked.
Primary outcome was all-cause mortality during hospital 
admission. Secondary outcomes were identiﬁ ed a priori 
as relevant to speciﬁ c poisons. For organophosphorus or 
carbamate pesticides,24 secondary outcomes were 
intubation, time ventilated, and seizures. For oleander, 
outcome was occurrence of cardiac dysrhythmias needing 
digoxin-speciﬁ c antibody fragments25  or serum potassium 
greater than 6·0 mmol/L. Digoxin-speciﬁ c antibody 
fragments became unavailable after 3–4 months26 and 
6686 patients assessed for eligibility
4632 randomised
1554 allocated to no
           activated charcoal
0 lost to follow-up 1 lost to follow-up
    transferred to another
    hospital, outcome not
    determined
2 lost to follow-up
    transferred to another
    hospital, outcome not
    determined
1554 analysed 1544 analysed 1531 analysed
1545 allocated to single-dose
            activated charcoal
1533 allocated to multiple-dose
           activated charcoal
<5%* did not receive allocated
            intervention (reasons
            included damaged throat
            and refusal)
2054 (31%) excluded
            1686 met exclusion criteria
               368 refused to participate
<5%* did not receive allocated
            intervention (reasons
            included damaged throat
            and refusal)
Figure 1: Trial proﬁ le
*The proportion of patients who did not receive their intervention is an estimate derived from a prospective study of compliance in 1649 participants.31
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patients were then transferred for temporary pacing with 
the same criteria. Therefore, this secondary outcome was 
then modiﬁ ed to become need for digoxin-speciﬁ c 
antibody fragments or transfer for pacing.
Patients were seen by study doctors within 30 min of 
admission. Their airway was stabilised and oxygen, 
atropine, ﬂ uids, and antidotes given as necessary. Gastric 
decontamination was only started when patients were 
stable. Gastric lavage or emesis, but not charcoal, was 
previously given in hospital clinical practice.27 In 
accordance with position papers about ipecac-induced 
forced emesis28 and gastric lavage29 published by the 
international associations of clinical toxicology, we 
initially did not give either to recruited patients. However, 
from patient number 1905 onwards, after much 
discussion within the national doctors union, all patients 
presenting less than 2 h after ingestion of large amounts 
of moderate-toxicity to high-toxicity pesticides or high 
doses of toxic medications (eg, tricyclic antidepressants) 
received gastric lavage with 300 mL of water three times 
at the request of the consultant physicians.
Patients remained under the care of consultant 
physicians using management protocols that had been 
agreed with the study team. The ward team made 
decisions about intubation and transfer of patients to 
intensive care20 or for cardiac pacing independently of 
study doctors. Patients were ﬁ rst managed on the medical 
ward; those needing intubation or inotropes were 
transferred to intensive care as a bed became available. 
All who died had a judicial post mortem.
Ethics approval was received from the Oxfordshire 
Clinical Research Ethics Committee and Faculty of 
Medicine Ethics Committee, Colombo. Written informed 
consent was obtained from each patient, or their relative 
(for patients unconscious or <16 years of age), in their 
own language. An independent data monitoring and 
ethics committee (IDMEC) was established for the trial. 
Interim analyses were to be supplied by the trial 
statistician to the IDMEC Chair as often as requested. In 
view of interim data, and emerging evidence from other 
studies, the IDMEC then informed the principal 
investigator if, in the committee’s view, there was proof 
beyond reasonable doubt that the data showed that any 
part of the protocol under investigation became clearly 
indicated or contraindicated, either for all participants or 
for a speciﬁ c subgroup of trial participants, or it was 
evident that no clear outcome would be obtained.
Statistical analysis
We calculated that to detect whether multiple-dose 
activated charcoal reduced the case fatality from 10%10 
to 7%, with a signiﬁ cance of 5% and power of 80%, a 
minimum of 1400 patients was needed in each group 
(4200 patients overall). 
Demographic factors and clinical characteristics were 
summarised with counts (percentages) for categorical 
variables, mean (SD) for normally distributed continuous 
variables, or median (IQR) for other continuous variables. 
We did an intention-to-treat analysis on all patients with 
available outcomes data (loss to follow-up of three 
[<1%] patients) analysed in the groups to which they were 
No charcoal 
(n=1554)
Single-dose 
activated charcoal 
(n=1545)
Multiple-dose 
activated 
charcoal (n=1533)
Women 639 (41%) 662 (43%) 573 (37%)
Age (years; median, IQR) 25 (19–35) 25 (19–35) 25 (19–36)
Toxin reported to have been ingested
Oleander (Thevetia peruviana) seeds 555 (36%) 550 (36%) 542 (35%)
Organophosphorus or carbamate pesticide 441 (28%) 440 (28%) 429 (28%)
Organochlorine 4 (<1%) 3 (<1%) 3 (<1%)
Other or unknown pesticide or paraquat 343 (22%) 340 (22%) 345 (23%)
Medicine or unknown 211 (14%) 212 (14%) 214 (14%)
Clinical status on admission
Asymptomatic 743 (48%) 745 (48%) 736 (48%)
Symptomatic with GCS 14 or 15 625 (40%) 621 (40%) 613 (40%)
Symptomatic with GCS <14 186 (12%) 179 (12%) 184 (12%)
Time between ingestion and hospital admission 
(h; median, IQR)
4·2 (2·7–7·0) 4·2 (2·7–7·1) 4·3 (2·7–7·1)
Information missing 14 19 14
Vomited since ingestion (prehospital admission) 809 (52%) 745 (48%) 767 (50%)
Previous forced emesis 832 (54%) 859 (56%) 812 (53%)
Previous gastric lavage 115 (7%) 118 (8%) 114 (7%)
Systolic blood pressure (mm Hg; mean, SD) 117·8 (17·5) 118·0 (16·2) 118·0 (16·1)
Information missing 97 111 116
Pulse (beats per min; mean, SD) 90·5 (20·1) 90·0 (19·6) 89·3 (19·5)
Information missing 7 16 18
Data are number (%), unless otherwise indicated. GCS=Glasgow coma score.
Table 1: Demographic and baseline characteristics (intention-to-treat population)
No AC 
(n=1554)
SDAC 
(n=1544)
MDAC 
(n=1531)
Odds ratio (95% CI)
MDAC vs no AC SDAC vs no AC MDAC vs SDAC
Died 105 
(6·8%)
109 
(7·1%)
97 
(6·3%)
0·93 (0·69–1·25)*
0·96 (0·70–1·33)†
1·05 (0·79–1·40)*
1·11 (0·82–1·52)†
0·89 (0·66–1·19)*
0·87 (0·64–1·18)†
Needing intubation for ventilation
Baseline 75 71 66
Follow-up 76 
(4·9%)
73 
(4·7%)
73 
(4·8%)
0·97 (0·69–1·37)*
0·96 (0·67–1·37)†
0·97 (0·68–1·36)* 
0·96 (0·67–1·37)†
1·01 (0·71–1·43)*
1·02 (0·71–1·45)†
Seizures
Baseline 9 8 7
Follow-up 7
(0·5%)
13 
(0·8%)
14 
(0·9%)
2·04 (0·77–5·99)*
1·92 (0·75–4·94)‡
1·88 (0·69–5·57)*
1·98 (0·78–5·06)‡
1·09 (0·47–2·52)*
0·97 (0·44–2·14)‡
Data are number or number (%). AC=activated charcoal. SDAC=single-dose activated charcoal. MDAC=multiple-dose 
activated charcoal. *Exact CIs. †Logistic regression adjusted for stratiﬁ cation factors: severity status on admission 
(categories asymptomatic=1 [reference category]; symptomatic with Glasgow coma score [GCS] 14/15=2; and 
symptomatic with GCS <14=3); toxin stated to have been ingested (categories oleander [Thevetia peruviana]=1 
[reference category]; organophosphorus or carbamate pesticides=2; organochlorine=3; other or unknown pesticide or 
paraquat=4; medicine or unknown=5); reported time between poisoning and randomisation (continuous: linear and 
quadratic terms), hospital site (categories Anuradhapura=1 [reference category]; Kurunegala=2; Polonnaruwa=3); and 
whether intubated at baseline (categories: no=0 [reference category]; and yes=1). ‡As † plus term for presence of 
seizures at baseline (categories: no=0 [reference category]; and yes=1].
Table 2: Summary of outcomes overall plus comparative statistics (intention-to-treat population)
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interaction
Test for
p value
MDAC No AC
0·5
0·9
0·2*
0·1*
Odds ratio
Favours MDAC Favours no AC
0·2 0·5 1·0 2·0 5·0 10·0
Odds ratio
(95% CI) 
Number of events
Poison suspected
OP and carbamate 0·78 ( 0·51–1·19) 43/429 55/441
Oleander 0·98 ( 0·55–1·77) 23/540 24/555
Other/unknown pesticide and paraquat 0·95 ( 0·52–1·73) 22/345 23/343
Medicine 3·06 ( 0·12–75·6)    1/160   0/162
Unknown 2·94 ( 0·56–15·3)   6/54   2/49
Poison conﬁrmed
OP and carbamate 0·82 ( 0·54–1·24) 45/460 54/461
Oleander 0·98 ( 0·55–1·76) 23/541 24/555
Other/unknown pesticide and paraquat 0·79 ( 0·42–1·48) 18/331 23/337
Medicine 3·08 ( 0·12–76·1)   1/158   0/161
Unknown 1·50 ( 0·26–8·82)   6/11   4/9
Time since ingestion (h)
<2 1·06 ( 0·50–2·22) 15/214 15/225
between 2 and 4 0·99 ( 0·62–1·58) 37/478 39/500
between 4 and 7 0·83 ( 0·47–1·45) 24/442 28/432
7 or more 1·05 ( 0·55–2·01) 20/383 19/382
Severity
Asymptomatic 1·31 ( 0·65–2·65) 18/734 14/743
Symptomatic GCS 14/15 1·02 ( 0·62–1·69) 32/613 32/625
Symptomatic GCS <14 0·74 ( 0·47–1·16) 47/184 59/186
Overall 0·93 ( 0·70–1·24) 97/1531            105/1554
Figure 2: Forest plot of mortality for multiple-dose activated charcoal versus no activated charcoal
MDAC=multiple-dose activated charcoal. AC=activated charcoal. OP=organophosphorus. GCS=Glasgow comma score. *Test for trend.
Odds ratio
Favours SDAC Favours no AC
0·2 0·5 1·0 2·0 5·0 10·0
interaction
Test for
p value
SDAC No AC
Odds ratio
(95% CI) 
Number of events
0·7
0·9
0·7*
0·1*
Poison suspected
OP and carbamate 0·94 (0·63–1·41)
Oleander 1·10 (0·62–1·94)
Other/unknown pesticide and paraquat 1·06 (0·58–1·91)
Medicine 5·33 (0·25–111·9)
Unknown 2·22 (0·41–12·0)
Poison conﬁrmed
OP and carbamate 1·00 (0·67–1·49)
Oleander 1·10 (0·62–1·94)
Other/unknown pesticide and paraquat 0·85 (0·46–1·58)
Medicine 5·26 (0·25–110·5)
Unknown 1·25 (0·21–7·62)
Time since ingestion (h)
<2 1·29 (0·64–2·61)
between 2 and 4 0·89 (0·55–1·44)
between 4 and 7 1·06 (0·62–1·80)
7 or more 1·26 (0·68–2·34)
Severity
Asymptomatic 1·36 (0·68–2·74)
Symptomatic GCS 14/15 1·28 (0·79–2·06)
Symptomatic GCS <14 0·83 (0·53–1·31)
Overall 1·05 (0·79–1·38)
52/440
26/549
24/340
2/154
5/58
53/454
26/549
20/340
2/155
5/10
19/225
33/471
30/440
24/388
19/745
40/620
50/179
109/1544
55/441
24/555
23/343
0/162
2/49
54/461
24/555
23/337
0/161
4/9
15/225
39/500
28/432
19/382
14/743
32/625
59/186
105/1554
Figure 3: Forest plot of mortality for single-dose activated charcoal versus no activated charcoal
SDAC=single-dose activated charcoal. AC=activated charcoal. OP=organophosphorus. GCS=Glasgow comma score. *Test for trend.
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allocated. For the primary analysis, we reported the 
number and proportion of patients having an event. To 
establish the magnitude and direction of the treatment 
eﬀ ect, we calculated the odds ratio (OR; plus exact 95% CI). 
We used logistic regression to compare the groups, 
estimate the OR (95% CI), and adjust for stratiﬁ cation 
factors and for geographical centre and baseline value 
(where appropriate).
The use of logistic regression was extended for the 
primary outcome to investigate the eﬀ ects of potentially 
important prognostic factors such as previous 
administration of gastric lavage and forced emesis (by test 
of interaction), perform prespeciﬁ ed subgroup analyses 
with the test of interaction to examine whether the 
treatment eﬀ ects were consistent across poison subgroups 
(suspected and conﬁ rmed), and test for trends in treatment 
eﬀ ects for reported time from ingestion to randomisation 
and illness severity on admission. Poison-speciﬁ c analyses 
were initially done for the groups identiﬁ ed on admission. 
Since the poison was sometimes identiﬁ ed only after 
randomisation (eg, patients randomised in the unknown 
poison group), analyses were then repeated including all 
patients identiﬁ ed as having ingested the poison.
Role of the funding source
The funding source had no role in study design, data 
collection, data analysis, and data interpretation; or 
writing of the report; or in the decision to submit for 
publication. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
Patients were enrolled from March 31, 2002, in 
Anuradhapura and June 04, 2002, in Polonnaruwa, and 
from Nov 23, 2002, to Feb 03, 2003, in Kurunegala. The 
target sample size was reached in September, 2004. Data 
were then reviewed by IDMEC at its ﬁ nal planned 
analysis. Recruitment was stopped on Oct 16, 2004, as 
per IDMEC recommendation.
Figure 1 shows the trial proﬁ le. Table 1 shows baseline 
demographic and clinical characteristics in the three 
groups. Median time from ingestion to randomisation 
was similar. Although patients were eligible up to 72 h 
after ingestion, very few presented after 24 h—108 (2%) 
of 4632 presented between 24 h and 48 h and 11 (<1%) 
of 4632 between 48 h and 72 h. 2338 (51%) patients had 
ingested pesticides—1310 had ingested organo phosphorus 
or carbamate pesticides, whereas 1647 (36%) had ingested 
oleander seeds. Median age was the same in each group 
(overall range 14–92 years).
Overall mortality in the trial was 311 (6·7%) of 4629. 
Multiple-dose activated charcoal did not reduce mortality 
(table 2); however, fewer patients receiving multiple-dose 
activated charcoal died than those receiving no charcoal 
(table 2; ﬁ gure 2). The trend towards increased treatment 
eﬀ ect with increased severity on admission was not 
signiﬁ cant (p=0·1). We did not note a trend between 
treatment eﬀ ect and time from ingestion to treatment. 
Reduction in mortality for patients who had ingested 
organophosphorus or carbamate pesticides and received 
multiple-dose activated charcoal was not signiﬁ cant 
(OR 0·78, 95% CI 0·51–1·19); this reduction was greater 
for diethyl organo phosphorus poisoning than for 
dimethyl organo phosphorus poisoning (webﬁ gure 1).
Comparison of single-dose activated charcoal versus no 
charcoal (ﬁ gure 3) and multiple-dose activated charcoal 
versus single-dose activated charcoal did not provide any 
evidence that charcoal aﬀ ected mortality (webﬁ gures 2–4). 
We did not note a consistent trend between treatment 
eﬀ ect and either severity on admission or time from 
ingestion to treatment. We did not ﬁ nd any evidence of a 
A   Cumulative percentage dying
B   Cumulative percentage intubated
Pe
rc
en
ta
ge
 d
ie
d
0
0
2 4 6 8 10 12 14
Days to death
1
2
3
4
5
6
7
8
Pe
rc
en
ta
ge
 in
tu
ba
te
d 
po
st
 ra
nd
om
isa
tio
n
Number at risk
 (deaths):
MDAC
No AC
SDAC
0
1
2
3
4
5
6
1529 (63)
1554 (74)
1540 (73)
1466 (10)
1480 (12)
1467 (11)
1456 (9)
1468 (5)
1456 (8)
1447 (5)
1463 (4)
1448 (5)
1442 (1)
1459 (2)
1443 (3)
1441 (2)
1457 (1)
1440 (2)
1439 (2)
1456 (2)
1438 (2)
1437
1454
1436
0 1 2 3 4 5 6 7 8
Days to ﬁrst intubation
Number at risk 
(intubations):
MDAC
No AC
SDAC
1505 (53)
1517 (50)
1513 (44)
1452 (5)
1467 (7)
1469 (12)
1447 (6)
1460 (11)
1457 (9)
1441 (5)
1449 (4)
1448 (5)
1436 (2)
1445 (3)
1443 (2)
1434 (0)
1442 (0)
1441 (1)
1434 (0)
1442 (0)
1440 (0)
1434 (1)
1442 (1)
1440 (0)
1433
1441
1440
MDAC
No AC
SDAC
Figure 4: Cumulative percentage—for days to death (A) and to ﬁ rst intubation (B)
(A) For the purpose of survival analysis, the clock was started at randomisation and stopped either at death or 
discharge (assumed to be 35 days if discharged alive sooner than 35 days). (B) For the purpose of survival analysis, 
the clock was started either at randomisation or, in the case of those who were intubated at randomisation, when 
the patient was ﬁ rst extubated. The clock stopped either at the ﬁ rst postrandomisation intubation or at death or 
discharge (assumed to be 8 days if discharged without intubation after less than 8 days). MDAC=multiple-dose 
activated charcoal. AC=activated charcoal. SDAC=single-dose activated charcoal.
See Online for webﬁ gures 1–4
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beneﬁ cial eﬀ ect of charcoal on time to death (ﬁ gure 4) and 
most of the deaths occurred within the ﬁ rst 24 h in all 
poison groups. Multivariate logistic regression showed no 
eﬀ ect (no evidence of an interaction) of our change in 
gastric lavage policy 12 months into the trial (in which all 
patients presenting within 2 h of a serious ingestion 
received lavage; data not shown).
Neither multiple-dose nor single-dose activated charcoal 
reduced the need for intubation, the rate of seizures, or 
(in oleander poisoning) cardiac dysrhythmias (tables 2 
and 3). A similar proportion of patients needed intubation 
in each group; no diﬀ erence was recorded in the time to 
ﬁ rst intubation (ﬁ gure 4). Median duration of ventilation 
(excluding deaths) was similar with multiple-dose 
activated charcoal (83·8 [IQR 35·0–173·0] h) and no 
charcoal (88·5 [38·5–203·1] h), but longer with single-dose 
activated charcoal (112·0 [36·6–234·9] h). Analyses were 
repeated, as stated in the protocol, after reclassiﬁ cation of 
cases in which the poison was identiﬁ ed after 
randomisation. Reallocation of these cases did not 
tangibly aﬀ ect the ﬁ ndings for any analysis (ﬁ gures 2 
and 3; webﬁ gures 1–4).
Although routine forced emesis and gastric lavage are 
no longer recommended internationally for self-poisoned 
patients, most had received mechanical forced emesis 
(2503 [54·0%] of 4632) or gastric lavage (347 [7·5%] 
of 4632), or both (64 [1·4%] of 4632), in a peripheral 
hospital before transfer. We used logistic regression 
analysis to assess whether previous gastric 
decontamination at the referring hospital aﬀ ected the 
results of this study for the primary outcome—ie, death. 
We saw no evidence of an interaction with either forced 
emesis or gastric lavage for each of the treatment 
comparisons (data not shown).
439 patients were admitted within 2 h of poison ingestion 
and allocated to either multiple-dose (n=214) or single-dose 
activated charcoal (n=225; ﬁ gures 2 and 3). The 
demographic and clinical baseline characteristics of early 
and late arrivals (deﬁ ned as before or after 2 h, respectively) 
were very similar with respect to age, blood pressure, sex, 
severity of symptoms, intubation, and seizures. Oleander 
poisoning featured more commonly in late arrivals 
(1497 [38%] of 3919) than in early arrivals (141 [21%] of 664). 
Most patients who presented late were transfers from other 
hospitals in which they had received forced emesis or 
gastric lavage. Comparison of these 439 patients with 225 
who were admitted within 2 h of poison ingestion and 
allocated to no charcoal (ﬁ gure 5) did not show evidence of 
beneﬁ t on death of early charcoal administration (34 of 439 
vs 15 of 225; OR 1·18 [exact 95% CI 0·61–2·38]; test of 
interaction p=0·5). Additionally, there was no evidence of 
an interaction between early charcoal administration and 
any of the secondary outcomes.
Administration of charcoal seemed safe. Despite 
2957 patients ingesting poisons (1647 oleander and 
1310 organophosphorus or carbamate pesticides) that are 
treated with atropine, which would reduce bowel motility, 
only two were referred for surgical review for acute 
abdomen. None of the patients who died in the study had 
substantial quantities of charcoal in their lungs at judicial 
post-mortem examination.
The number of patients with absent bowel sounds on 
abdominal auscultation was small—17 (1·1%) of 1531 
receiving multiple-dose activated charcoal, seven (0·5%) 
of 1544 receiving single-dose activated charcoal, and 
17 (1·1%) of 1554 receiving no charcoal. A small 
non-signiﬁ cant increase in the occurrence of seizures 
was seen in patients receiving either regimen of charcoal 
compared with no charcoal (table 2).
Discussion
This randomised, controlled trial showed no beneﬁ t from 
routine administration of multiple-dose activated charcoal 
in Sri Lankan district hospitals. Most patients had 
ingested yellow oleander seeds or pesticides. Both poisons 
have major eﬀ ects that are delayed for several hours, most 
deaths from oleander seeds occurred after 12 h (data not 
shown), and the median time to intubation and death 
after admission for all poisoned patients was 12–24 h 
(ﬁ gure 4), potentially giving multiple-dose activated 
charcoal time to work. Absence of beneﬁ t was seen 
irrespective of the poison ingested or time to presentation. 
A non-signiﬁ cant trend towards beneﬁ t with charcoal was 
seen in the most ill patients at admission.
In 2003, de Silva and co-workers30 published the results 
of a single-blind, randomised, placebo-controlled trial 
investigating the eﬀ ect of multiple-dose activated 
charcoal in yellow oleander poisoning. They reported a 
No AC SDAC MDAC Odds ratio (95% CI)
MDAC vs no AC SDAC vs no AC MDAC vs SDAC
Number 441 440 429
Patients with reported organophosphorus or carbamate poisoning needing intubation for ventilation
Baseline 63 51 48
Follow-up 53 
(12·0%)
48 
(10·9%)
50 
(11·7%)
0·97 (0·63–1·49)* 
0·90 (0·58–1·41)†
0·90 (0·58–1·39)*
0·83 (0·54–1·29)†
1·08 (0·69–1·68)*
1·12 (0·72–1·74)†
Seizures
Baseline 7 2 2
Follow-up 2
(0·5%)
7
(1·6%)
6
(1·4%)
3·11 (0·55–31·67)* 
3·15 (0·61–16·18)‡
3·55 (0·67–35·15)*
3·44 (0·70–16·81)‡
0·88 (0·24–3·08)*
0·89 (0·29–2·.71)‡
Number 555 549 540
Patients with reported oleander (Thevetia peruviana) poisoning given cardiac pacing or antitoxin
Baseline 2 2 1
Follow-up 101 
(18·2%)
101 
(18·4%)
85 
(15·7%)
0·84 (0·60–1·17)* 
0·85 (0·61–1·18)§
1·01 (0·74–1·40)*
1·02 (0·74–1·41)§
0·83 (0·60–1·15)*
0·82 (0·59–1·14)§
Data are number or number (%). AC=activated charcoal. SDAC=single-dose activated charcoal. MDAC=multiple-dose 
activated charcoal. *Exact CIs. †Logistic regression adjusted for stratiﬁ cation factors: severity status on admission 
(categories asymptomatic=1 [reference category]; symptomatic with Glasgow coma score [GCS] 14/15=2; and 
symptomatic with GCS <14=3); reported time between poisoning and randomisation (continuous: linear and 
quadratic terms); hospital site (categories: Anuradhapura=1 [reference category]; Kurunegala=2; and Polonnaruwa=3); 
and whether intubated at baseline (categories: no=0 [reference category]; and yes=1). ‡As † plus term for presence of 
seizures at baseline (categories: no=0 [reference category]; and yes=1). §As † plus term for whether patient received 
cardiac pacing at baseline (categories: no=0 [reference category]; and yes=1).
Table 3: Summary of poison-speciﬁ c outcomes plus comparative statistics (intention-to-treat population)
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case fatality with multiple-dose activated charcoal of 
ﬁ ve (2·5%) of 201 patients versus 16 (8%) of 200 with 
single-dose activated charcoal (p=0·025, relative risk 
[RR] 0·31, 95% CI 0·12–0·83). The corresponding 
comparison in our study showed deaths in 23 (4·3%) 
of 540 patients given multiple-dose activated charcoal 
versus 26 (4·7%) of 549 given single-dose activated 
charcoal; a result showing a small non-signiﬁ cant beneﬁ t 
in favour of multiple-dose activated charcoal 
(0·90, 0·52–1·56). A longer regimen was given in 
de Silva and co-workers’ study30—50 g every 6 h for 
12 doses during 72 h—than in our study—50 g every 4 h 
for six doses during 20–24 h. However, 87% of 
oleander-induced deaths occurred within 24 h of 
admission, indicating that the continuation of charcoal 
therapy after 24 h could not account for the major 
diﬀ erence in eﬀ ectiveness of multiple-dose activated 
charcoal between studies.
We do not think that absence of beneﬁ t in our study 
was caused by poor compliance. Although we could not 
objectively measure it, we did estimate compliance in 
1103 patients receiving charcoal in two study hospitals.31 
Overall, patients ingested 80% of their ﬁ rst dose; and 
thereafter compliance decreased for further doses 
until 60% of the sixth dose was ingested.31 Compliance 
was not formally measured in de Silva and colleagues’ 
study,30 but they reported that “none refused to take it”. 
This ﬁ nding contrasts with our absolute refusal rates 
of 2% for the ﬁ rst dose, increasing to 12% by the sixth 
dose.31 However, such diﬀ erences are unlikely to have 
caused the eﬀ ect we report. Nor does it seem likely that 
the diﬀ erence was caused by the charcoal used—
Carbomix is used widely worldwide and has a surface 
area of 2000 m2/g compared with Haycarb (Hayes, 
Colombo, Sri Lanka; 1600 m2/g), which de Silva and 
colleagues’ used.30  Overall, the combined evidence does 
not suggest a major eﬀ ect of charcoal administration in 
oleander poisoning.
No beneﬁ t was noted from single-dose activated charcoal 
(or from the ﬁ rst dose of multiple-dose activated charcoal). 
Our study was not speciﬁ cally designed to look at patients 
presenting within 2 h, in whom single-dose activated 
charcoal is proposed to have its major eﬀ ect on reduction 
of poison absorption.14 The median time to admission in 
our trial was longer than 2 h; only 664 patients presented 
within 2 h. However, many patients had ingested oleander 
seeds, which are slowly absorbed over many hours19 and 
single-dose activated charcoal was worse than no charcoal 
in these patients (ﬁ gure 3).
The absence of eﬀ ect of single-dose activated charcoal 
in our study contrasts with studies of volunteers 
receiving pharmaceutical drugs that reduced absorption 
when single-dose activated charcoal was given early14 
and also contrasts with a pharmacokinetic study that 
showed increased clearance in patients with moderate 
oleander poisoning.19 However, subtoxic doses of 
pharmaceutical drugs were given to the volunteers and 
these doses were probably far less than those that 
produced clinical outcomes in our study. Furthermore, 
charcoal is most likely to be eﬀ ective with highly toxic 
poisons that cause clinical eﬀ ects at small doses.14 Sri 
Lanka has banned the most toxic WHO class I pesticides, 
leaving only a few moderately toxic pesticides. The 
pharmacokinetic study that showed diﬀ erences in 
oleander poisoning19 did not include patients with major 
clinical outcomes occurring within 24 h, suggesting that 
higher doses of poison were ingested by patients in our 
randomised controlled trial.
Mortality in the control no charcoal group was lower 
than predicted for two main reasons. First, frequent 
careful monitoring by the study team, its use of protocols, 
and administration of gastric lavage27 during resuscitation 
to only a few patients resulted in a substantial reduction 
in deaths for the patients recruited to the trial (data not 
shown). Second, because of poor outcome after paraquat 
ingestion, hospital doctors were not in equipoise for 
Time since ingestion (min)
0·37 ( 0·01–9·98)   0/10 1/12
1·59 ( 0·41–6·15)   9/96 3/49
0·49 ( 0·17–1·45)    7/156 7/80
2·26 ( 0·74–6·91) 18/177 4/84
0·34 ( 0·14–0·80) 10/219     13/105
1·27 ( 0·64–2·54) 28/245     13/141
0·95 ( 0·39–2·29) 15/247    8/125
1·91 ( 0·69–5·30) 17/238    5/129
0·94 ( 0·59–1·51) 54/882    28/432
1·16 ( 0·67–2·01) 44/771    19/382
≤30 
31–60 
61–90 
91–120 
121–150 
151–180 
181–210 
211–240 
Between 240 and 420
420 or more
Odds ratio
Favours any AC Favours no AC
0·2 0·5 1·0 2·0 5·0 10·0
Any AC No AC
Odds ratio
(95% CI) 
Number of events
Figure 5: Forest plot of eﬀ ect of time to recruitment on mortality for multiple-dose or single-dose activated charcoal versus no activated charcoal, with 
detailed breakdown of less than 4 h
AC=activated charcoal.
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patients with paraquat poisoning and wanted to give 
Fuller’s earth or single-dose activated charcoal. Therefore 
few paraquat-poisoned patients were recruited, lowering 
overall mortality.
The fewer than predicted number of events reduced 
the power of our trial. However, at the third planned 
interim analysis, when the prespeciﬁ ed recruitment 
target had been reached, the IDMEC considered the 
likelihood of ﬁ nding a clinically meaningful beneﬁ t from 
giving charcoal if the trial was extended over and beyond 
the original target sample size. After assessment of the 
accumulating evidence from this trial, the IDMEC 
recommended that the trial terminate recruitment.
Another limitation was the absence of masking. We 
believed that masking was diﬃ  cult because of the 
impossibility to conceal from a reviewing doctor whether 
a patient had received any charcoal. An absence of masking 
might have allowed for performance bias for the secondary 
outcomes. To counter this potential bias, the medical team 
made decisions about intubation and transfer of patients 
independently of the study doctors. This pragmatic 
response to an issue of internal validity was regarded as 
acceptable since the primary outcome—death during the 
admission—was unambiguous.
The poisons ingested by our study patients were typical 
of rural Asia. Unlike western countries, where patients 
generally ingest pharmaceuticals with varying mechanisms 
of action, most patients in our study took two types of 
poisons—anticholinesterase pesticides (28·3%) and 
cardenolides (35·6%). The large number of patients 
ingesting these two types of poisons suggests that the 
results are especially applicable to them.
We believe our study is relevant to rural Asia because it 
shows that routine multiple-dose activated charcoal 
administration is unlikely to be beneﬁ cial even in 
locations with high case-fatalities in which an intervention 
might be expected to oﬀ er greatest beneﬁ t. Our study 
shows that multiple-dose activated charcoal is not 
indicated for oleander poisoning or for organophosphorus 
and carbamate pesticides—all common and highly toxic 
poisons across the region.
We were not able to assess the eﬀ ect of early 
administration of single-dose activated charcoal on 
outcome since few patients presented within 2 h. The 
OR 95% CI stretched from 0·61 to 2·38, suggesting 
little likelihood of beneﬁ t. However, our results might 
be useful in establishing a cluster randomised controlled 
trial in rural hospitals with the aim of recruiting large 
numbers of patients presenting within 2 h, especially 
those with a GCS of less than 14 on admission.
Intentional self-poisoning continues to kill many 
people throughout rural Asia. We have little evidence on 
which to base medical therapy of pesticide poisoning 12 
and eﬀ ective treatments for oleander poisoning are often 
unaﬀ ordable.26 Clinical trials to identify eﬀ ective therapy 
and new therapeutic interventions with which to prevent 
these unnecessary deaths are urgently needed.
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